On April 11, 2019, the Department of Justice Antitrust Division will hold a public roundtable to discuss the Antitrust Criminal Penalty Enhancement & Reform Act (ACPERA). ACPERA reduces the civil damages exposure of a company granted leniency under the Antitrust Division’s Leniency Policy if the company provides civil plaintiffs with timely, “satisfactory cooperation.” ACPERA, Section 213(b) & (c), 15 U.S.C. § 1 notes. The Antitrust Division seeks to hear the views of interested stakeholders regarding ACPERA and its impact on the Division’s criminal enforcement efforts.
The ACPERA Roundtable will provide a public forum for the Antitrust Division to engage with the antitrust community and gain insight from judges, attorneys, economists, academics, the business community, and other interested stakeholders on ACPERA. The format of the Roundtable will be a series of panel discussions with featured speakers.
“The Division’s Leniency Policy is critical to the success of our criminal enforcement program. I am proud to have been at the Division when ACPERA was enacted in 2004 and the Antitrust Division looks forward to examining how ACPERA is operating today,” said Assistant Attorney General Makan Delrahim. “The Division values input from those who have experience with ACPERA and other stakeholders who have considered ACPERA’s effects on the self-disclosure of wrongdoing.”
The roundtable will take place from 1-5 p.m., on April 11, 2019, in the Anne K. Bingaman Auditorium & Lecture Hall on the lower level of the Liberty Square Building, 450 Fifth Street, NW, Washington, DC 20530.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas